The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

​Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the Best Growth Stocks to Buy and Hold for the Next Decade. On June 17, BTIG maintained a Buy rating on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) with a $22 price target. The rating is based on two significant announcements from the company.

​Firstly, Adaptive announced an upsized convertible notes offering of $300 million, up from the originally planned $250 million. Secondly, the company also revealed its plans to separate its MRD and immune medicine businesses. BTIG views both moves positively as it has long considered the immune medicine unit non-core, and believes spinning it off will help unlock greater value in the core MRD business.

​The firm noted that while the shares of Adaptive dipped slightly due to technical nuances around the convertible notes offering, BTIG wasn't concerned. In fact, the firm, after talking with management, came back reassured that both announcements reflect a position of strength, with strong momentum across all MRD applications.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is involved in the development of an immune medicine platform, with its services and products including immunoSEQ, clonoSEQ, cellular therapy, and vaccines.

While we acknowledge the potential of ADPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.